Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

ZMapp: Best Anti-Ebola Drug Yet

September 3, 2014 10:15 am | by Cynthia Fox, Science Editor | Articles | Comments

ZMapp, the experimental drug that may have already have saved a few patients in Africa, is the most effective anti-Ebola therapy yet, according to a recent Nature paper on rhesus macaques monkeys. Read more...           

TOPICS:

AstraZeneca Releases Phase 4 Brilinta Data

September 2, 2014 3:35 pm | News | Comments

AstraZeneca announced the results of the Phase 4 ATLANTIC study, which indicates that the profile of Brilinta/Brilique (ticagrelor) is comparable whether administered in a pre-hospital or in-hospital setting to ST segment elevation myocardial infarction (STEMI) patients. Read more...

TOPICS:

FDA Names Myelofibrosis Treatment an Orphan Drug

September 2, 2014 3:25 pm | News | Comments

Promedior Inc. announced that the FDA has granted an orphan drug designation for PRM-151, for the treatment of myelofibrosis, a serious, life-limiting cancer characterized by fibrosis of the bone marrow. Read more...         

TOPICS:
Advertisement

Ipsen's Somatuline Gets Priority Review

September 2, 2014 3:16 pm | News | Comments

Ipsen N.A. announced that the FDA has accepted and granted priority review of its supplemental New Drug Application for Somatuline Depot 120mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors. Read more...      

TOPICS:

Scientists Make Diseased Cells Synthesize Their Own Drug

September 2, 2014 3:08 pm | News | Comments

In a new study that could ultimately lead to many new medicines, scientists have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy. Read more...     

TOPICS:

Amgen Submits MAA for Melanoma Treatment

September 2, 2014 2:59 pm | News | Comments

Amgen announced the submission of a Marketing Authorization Application to the European Medicines Agency via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Read more...

TOPICS:

World is ‘Losing Battle Against Ebola,’ Group Says

September 2, 2014 2:53 pm | by Alexandra Olson and Sarah DiLorenzo | News | Comments

The international group Doctor Without Borders warned Tuesday that the world is losing the battle against Ebola and lamented that treatment centers in West Africa have been "reduced to places where people go to die alone" as authorities race to contain the disease. Read more...

TOPICS:

Single Animal-to-Human Transmission Event Sparked 2014 Ebola Outbreak

September 2, 2014 10:32 am | News | Comments

Scientists used advanced genomic sequencing technology to identify a single point of infection from an animal reservoir to a human in the current Ebola outbreak in West Africa. Read more...                  

TOPICS:
Advertisement

Bayer Extends Xarelto Investigation to 275,000 Patients

September 2, 2014 10:24 am | News | Comments

Bayer HealthCare and its development partner Janssen Research & Development LLC announced an expansion of the global clinical development program for the oral Factor Xa inhibitor rivaroxaban for the prevention of potentially deadly blood clots in patients at risk of arterial thromboembolism. Read more...

TOPICS:

Daiichi Sankyo Expands Drug Discovery Collaboration in Europe

September 2, 2014 10:12 am | News | Comments

Daiichi Sankyo Co. Ltd. announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Program 2014, a collaborative drug discovery initiative for universities and research institutes in Europe. Read more...   

TOPICS:

Novo Nordisk Discontinues Inflammatory Disorder Activities

September 2, 2014 10:00 am | News | Comments

Novo Nordisk announced a decision to discontinue all its research and development (R&D) activities within inflammatory disorders. Read more...                              

TOPICS:

EC Approves Allergan's Ozurdex for DME

September 2, 2014 9:52 am | News | Comments

Allergan Inc. announced that the European Commission has extended the Marketing Authorization for Ozurdex to treat adult patients with visual impairment due to diabetic macular edema (DME). Read more...              

TOPICS:

Heart Failure Drug Cuts Deaths, Hospitalizations by 20%

September 2, 2014 9:44 am | News | Comments

A new study reports one of the biggest potential advances against heart failure in more than a decade— a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20%. Read more...          

TOPICS:

FDA Fast Tracks Pfizer's C.diff Vaccine

August 29, 2014 2:00 pm | News | Comments

Pfizer Inc. has announced  that the FDA has granted Fast Track designation to the company’s investigational Clostridium difficile vaccine candidate (PF-06425090). Read more...                 

TOPICS:

Amgen Submits BLA for Cholesterol-Lowering Pill

August 29, 2014 2:00 pm | News | Comments

Amgen has announced the submission of a Biologics License Application (BLA) to the FDA for evolocumab seeking approval for the treatment of high cholesterol. Read more...                       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading